DermTech Inc
NASDAQ:DMTK
Intrinsic Value
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. [ Read More ]
The intrinsic value of one DMTK stock under the Base Case scenario is 4.744 USD. Compared to the current market price of 0.702 USD, DermTech Inc is Undervalued by 85%.
Valuation Backtest
DermTech Inc
Run backtest to discover the historical profit from buying and selling DMTK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
DermTech Inc
Current Assets | 61.8m |
Cash & Short-Term Investments | 55.9m |
Receivables | 2.6m |
Other Current Assets | 3.3m |
Non-Current Assets | 60.2m |
PP&E | 56.7m |
Other Non-Current Assets | 3.5m |
Current Liabilities | 13.4m |
Accounts Payable | 1.5m |
Accrued Liabilities | 11.8m |
Other Current Liabilities | 213k |
Non-Current Liabilities | 51.3m |
Long-Term Debt | 38k |
Other Non-Current Liabilities | 51.3m |
Earnings Waterfall
DermTech Inc
Revenue
|
15.3m
USD
|
Cost of Revenue
|
-15m
USD
|
Gross Profit
|
276k
USD
|
Operating Expenses
|
-104m
USD
|
Operating Income
|
-103.7m
USD
|
Other Expenses
|
2.9m
USD
|
Net Income
|
-100.9m
USD
|
Free Cash Flow Analysis
DermTech Inc
What is Free Cash Flow?
DMTK Profitability Score
Profitability Due Diligence
DermTech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
DermTech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
DMTK Solvency Score
Solvency Due Diligence
DermTech Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
DermTech Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DMTK Price Targets Summary
DermTech Inc
According to Wall Street analysts, the average 1-year price target for DMTK is 2.856 USD with a low forecast of 1.515 USD and a high forecast of 4.2 USD.
Ownership
DMTK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DMTK Price
DermTech Inc
Average Annual Return | -5.62% |
Standard Deviation of Annual Returns | 106.48% |
Max Drawdown | -99% |
Market Capitalization | 24.2m USD |
Shares Outstanding | 34 623 400 |
Percentage of Shares Shorted | 9.38% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in La Jolla, California and currently employs 255 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. The company provides the Pigmented Lesion Assay (PLA), which is a gene expression test that enables early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The firm offers the Nevome test, which is an adjunctive reflex test for the PLA and is used with histopathology to identify additional risk factors for melanoma and confirm the diagnosis. Its Adhesive Skin Sample Collection Kit offers properties of the adhesive and a collection of informative cellular materials for its PLA. The Company’s Telemedicine Option for the PLA is the provision of health-related services and information through electronic information and telecommunication technologies.
Contact
IPO
Employees
Officers
The intrinsic value of one DMTK stock under the Base Case scenario is 4.744 USD.
Compared to the current market price of 0.702 USD, DermTech Inc is Undervalued by 85%.